Amylyx Pharmaceuticals, Inc.
AMLX
$13.91
-$0.15-1.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.44M | -35.91M | -37.55M | -72.70M | -72.70M |
| Total Depreciation and Amortization | 141.00K | 156.00K | 160.00K | 221.00K | 208.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.09M | 5.13M | 5.08M | 41.51M | 14.61M |
| Change in Net Operating Assets | 9.96M | -9.20M | -26.70M | -10.60M | -8.70M |
| Cash from Operations | -25.25M | -39.82M | -59.01M | -41.57M | -66.58M |
| Capital Expenditure | -17.00K | -11.00K | -20.00K | -36.18M | -89.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.01M | -43.65M | 65.00M | 75.00M | -28.87M |
| Cash from Investing | 22.99M | -43.66M | 64.98M | 38.82M | -28.96M |
| Total Debt Issued | 0.00 | 65.58M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 72.00K | 970.00K | 148.00K | 491.00K | 47.00K |
| Repurchase of Common Stock | -103.00K | -885.00K | -38.00K | -411.00K | -20.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -31.00K | 65.66M | 110.00K | 80.00K | 27.00K |
| Foreign Exchange rate Adjustments | 608.00K | 197.00K | -525.00K | 236.00K | -39.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.68M | -17.62M | 5.56M | -2.44M | -95.55M |